You are here:
(一)
NICE
(二)
NICE Guidance
(三)
Conditions and diseases
(四)
Mental health, behavioural and neurodevelopmental conditions
(五)
Bipolar disorder
●Technology appraisal guidance
●Reference number: TA59
●Published:
●
Last updated:
●
Guidance
●
Tools and resources
●
Information for the public
●
History
Download guidance (PDF)
●
Overview
●
1 Guidance
●
2 Clinical need and practice
●
3 The technology
●
4 Evidence and interpretation
●
5 Recommendations for further research
●
6 Implications for the NHS
●
7 Implementation and audit
●
Appendix A. Appraisal Committee members
●
Appendix B. Sources of evidence considered by the Committee
●
Appendix C. The use of electroconvulsive therapy
●
Appendix D. Detail on criteria for audit of the use of electroconvulsive therapy
●
Update information
Overview
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.
The recommendations on treating depression have been updated by the NICE guideline on depression.
Is this guidance up to date?
We reviewed the evidence in April 2014. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.
Guidance development process
How we develop NICE technology appraisal guidance
Your responsibility
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.